<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882775</url>
  </required_header>
  <id_info>
    <org_study_id>PJ-KY-2018-117</org_study_id>
    <nct_id>NCT03882775</nct_id>
  </id_info>
  <brief_title>Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction</brief_title>
  <acronym>BEST</acronym>
  <official_title>Bivalirudin vs Heparin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Dalian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an investigator-sponsored, prospective, multicenter, randomized, open-label
      study designed to compare efficacy and safety between bivalirudin and heparin in elderly
      patients with acute ST-segment elevation myocardial infarction undergoing emergency PCI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>7 days</time_frame>
    <description>a composite of cardiac death, reinfarction, heart failure,ischemic stroke,frequent post infarction angina，Ventricular tachycardia or fibrillation requiring electrical cardioversion or defibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>7 days</time_frame>
    <description>BARC types 3-5 bleeding;TIMI major bleeding or GUSTO moderate to severe bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>30 days</time_frame>
    <description>a composite of cardiac death, reinfarction, heart failure,ischemic stroke,frequent post infarction angina，Ventricular tachycardia or fibrillation requiring electrical cardioversion or defibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis ,TVR ,TLR</measure>
    <time_frame>30 days</time_frame>
    <description>rate of stent thrombosis,unplanned target-vessel revascularization and target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>180 days</time_frame>
    <description>a composite of cardiac death, reinfarction, heart failure,ischemic stroke,frequent post infarction angina，Ventricular tachycardia or fibrillation requiring electrical cardioversion or defibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis ,TVR ,TLR</measure>
    <time_frame>180 days</time_frame>
    <description>rate of stent thrombosis,unplanned target-vessel revascularization and target lesion revascularisation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>STEMI</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Aged</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>Patients would be given anticoagulant therapy with bivalirudin in acute STEMI during emergency PCI operation.</description>
    <arm_group_label>Bivalirudin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>heparin with or without gpi during emergency PCI.</description>
    <arm_group_label>Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥75 years old;

          -  Planned emergency (Symptom onset within 24h) PCI for acute STEMI patients;

          -  Life expectancy ≥ 1 year;

          -  Provide written informed consent.

        Exclusion Criteria:

          -  Contraindications to angiography or PCI;

          -  Active bleeding or bleeding constitution, bleeding tendency, including GI or urinary
             tract hemorrhage (3 months), cerebral hemorrhage (6 months) or cerebral infarction
             history (3 months), etc;

          -  Other disease may lead to vascular lesions and secondary bleeding factors (such as
             active gastric ulcer, active ulcerative colitis, intra-cerebral mass, aneurysm, etc.);

          -  Severe renal insufficiency (eGFR &lt; 30 mL/min/ 1.73 m2);

          -  Elevated AST, ALT level higher than three times of the normal upper limit;

          -  Advanced heart failure (NYHA classification grading of cardiac function ≥ Ⅲ)

          -  Complicated with immune system diseases；

          -  Abnormal hematopoietic system：platelet count &lt; 100 * 109 / L or ＞ 700 * 109 / L，white
             blood cell count &lt; 3 * 109/L etc;

          -  Suffering from acute infections ,infectious diseases or other serious diseases, such
             as malignant tumors;

          -  Known intolerance, or contraindication to any antithrombotic medication

          -  Known allergy to the study drugs and instruments (UFH, bivalirudin, aspirin and
             clopidogrel, stainless steel, contrast agents, etc.), or those allergic constitution.

          -  Non-cardiac co-morbid conditions are present that may result in protocol
             non-compliance;

          -  Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period;

          -  Patient's inability to fully cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongchong Huang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Dalian Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rongchong Huang, M.D.</last_name>
    <phone>+86 411 83635963</phone>
    <phone_ext>7127</phone_ext>
    <email>rchuang@dlmedu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Huang, M.D.</last_name>
      <phone>+86-411-83635963</phone>
      <phone_ext>3035</phone_ext>
      <email>dyyykjb@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yinan Wang, M.S.</last_name>
      <phone>+86-411-83635963</phone>
      <phone_ext>3015</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI; European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013 May;109(5):769-86. doi: 10.1160/TH12-06-0403. Epub 2013 Mar 28. Review.</citation>
    <PMID>23636477</PMID>
  </reference>
  <reference>
    <citation>Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. AHA Scientific Statement: Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):E9-9.</citation>
    <PMID>11451763</PMID>
  </reference>
  <reference>
    <citation>Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther. 2002 Jun;71(6):433-9.</citation>
    <PMID>12087346</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major adverse cardiac events (MACEs)</keyword>
  <keyword>bivalirudin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

